MANGALAM Stock Overview
Mangalam Drugs & Organics Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Mangalam Drugs & Organics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹100.75 |
| 52 Week High | ₹132.45 |
| 52 Week Low | ₹90.80 |
| Beta | 0.73 |
| 1 Month Change | 3.81% |
| 3 Month Change | -0.44% |
| 1 Year Change | -11.31% |
| 3 Year Change | -28.01% |
| 5 Year Change | 91.90% |
| Change since IPO | 739.58% |
Recent News & Updates
Little Excitement Around Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Revenues As Shares Take 25% Pounding
Mar 28
Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Shares Lagging The Industry But So Is The Business
Feb 07Recent updates
Little Excitement Around Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Revenues As Shares Take 25% Pounding
Mar 28Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Shares Lagging The Industry But So Is The Business
Feb 07Estimating The Fair Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)
Oct 20Is Mangalam Drugs & Organics (NSE:MANGALAM) A Risky Investment?
Mar 29These 4 Measures Indicate That Mangalam Drugs & Organics (NSE:MANGALAM) Is Using Debt Extensively
May 31A Look At The Fair Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)
Apr 06We Think Mangalam Drugs & Organics (NSE:MANGALAM) Is Taking Some Risk With Its Debt
Jan 03Here's Why Mangalam Drugs & Organics (NSE:MANGALAM) Can Manage Its Debt Responsibly
May 23Is Mangalam Drugs & Organics (NSE:MANGALAM) A Risky Investment?
Jan 04Do Its Financials Have Any Role To Play In Driving Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Stock Up Recently?
Nov 12
A Look At The Intrinsic Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)
Sep 20Does Mangalam Drugs & Organics's (NSE:MANGALAM) Statutory Profit Adequately Reflect Its Underlying Profit?
Aug 05We Think Mangalam Drugs & Organics (NSE:MANGALAM) Can Stay On Top Of Its Debt
Jul 01Shareholder Returns
| MANGALAM | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 1.6% | 1.4% | 2.8% |
| 1Y | -11.3% | 57.2% | 46.6% |
Return vs Industry: MANGALAM underperformed the Indian Pharmaceuticals industry which returned 55.9% over the past year.
Return vs Market: MANGALAM underperformed the Indian Market which returned 46.4% over the past year.
Price Volatility
| MANGALAM volatility | |
|---|---|
| MANGALAM Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: MANGALAM's share price has been volatile over the past 3 months.
Volatility Over Time: MANGALAM's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1972 | 523 | Govardhan Dhoot | www.mangalamdrugs.com |
Mangalam Drugs & Organics Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. It offers a range of API products, which include Acyclovir, Amodiaquine, Artemether, Artesunate, Atazanavir Sulfate, Bisoprolol Fumarate, Chloroquine Phosphate, Dihydroartemisinin, and Dolutegravir Sodium; Efavirenz, Emtricitabine, Furosemide, Hydroxychloroquine Sulphate, Lumefantrine, and Nimesulide; Nitrofurantoin Anhydrous and Monohydrate; Primaquine and Piperaquine Phosphate; Pregabalin, Pyrimethamine, Pyronaridine Tetraphosphate, and Sulfadoxine; and Tenofovir Alafenamide Hemifumarate and Disoproxil Fumarate. The company also offers intermediates comprising 2-Dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-Dichloro-5-methoxy pyrimidine; 4,7 Dichloroquinoline; Ortho phenoxy methane sulfonanilide; and Tenofovir Alafenamide Base and Disoproxil Base.
Mangalam Drugs & Organics Limited Fundamentals Summary
| MANGALAM fundamental statistics | |
|---|---|
| Market cap | ₹1.59b |
| Earnings (TTM) | -₹169.87m |
| Revenue (TTM) | ₹3.59b |
0.4x
P/S Ratio-9.4x
P/E RatioIs MANGALAM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MANGALAM income statement (TTM) | |
|---|---|
| Revenue | ₹3.59b |
| Cost of Revenue | ₹2.41b |
| Gross Profit | ₹1.19b |
| Other Expenses | ₹1.36b |
| Earnings | -₹169.87m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 30, 2024
| Earnings per share (EPS) | -10.73 |
| Gross Margin | 33.09% |
| Net Profit Margin | -4.73% |
| Debt/Equity Ratio | 71.4% |
How did MANGALAM perform over the long term?
See historical performance and comparison